Compugen Ltd. reported progress in its MAIA-ovarian trial for platinum-sensitive ovarian cancer, expecting median progression-free survival data by Q1 2027, a potential milestone for its COM701 antibody. The company also highlighted advancements in partnered programs with AstraZeneca and Gilead, including new data presentations and ongoing Phase 1 and 3 trials. Financially, Compugen holds $125.3 million in cash and expects funding to last into 2029, positioning it well to continue developing its immuno-oncology pipeline. This progress underscores Compugen's commitment to advancing novel cancer immunotherapies with AI-driven drug discovery.
AstraZeneca's shares fell 6% following reports of talks to acquire Bristol Myers Squibb, leaving analysts puzzled. Despite AstraZeneca's strong growth and innovation, brokers like Jefferies and UBS question the strategic timing and benefits of the de...
Alibaba unveiled its new AI model, Qwen3.8-Max, built on 2.4 trillion parameters, claiming performance comparable to top global AI systems. The model outperformed competitors in benchmarks and demonstrated autonomous coding by completing a software p...
AstraZeneca shares fell 7% after news emerged that it is in talks to buy US rival Bristol Myers Squibb, potentially forming a pharmaceutical group valued near $400 billion. This move would significantly expand AstraZeneca's presence in the US market ...
AstraZeneca is in talks with US rival Bristol Myers Squibb about a potential merger that could form one of the world's largest pharmaceutical companies valued at nearly $400 billion. The discussions have been ongoing for several months and may conclu...
UK pharmaceutical company AstraZeneca is in talks to merge with US rival Bristol Myers Squibb, potentially forming a combined entity valued at around $400 billion. The merger would be one of the largest in history, combining AstraZeneca's global reac...
